Radiotherapy in soft tissue sarcoma

SummaryRadiation therapy (RT) is an integral part of the treatment of adult soft tissue sarcomas (STS). In extremity STS, RT generally increases local control (LC) compared to wide excision alone while the magnitude of benefit depends on the individual risk profile. Neoadjuvant treatment results in less late toxicity paralleled by improved functional outcome but comes along with increased wound complications compared to postoperative radiation. In retroperitoneal sarcoma, neoadjuvant radiation seems to improve LC at least in liposarcomas while its impact in other histologies remains unclear. Postoperative radiation should not be used except in highly selected cases due to clear disadvantages regarding target coverage and side effects. The introduction of modern radiation techniques like intensity-modulated RT and image-guided RT has further improved the therapeutic ratio and is strongly recommended. Alternative boosting techniques like intraoperative RT or brachytherapy might be used to increase efficacy in high-risk patients although their value has not been proven in modern randomized trials.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

AbstractBackgroundPleomorphic liposarcomas (PLS) is an aggressive, high-grade subtype of soft tissue sarcoma representing  
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to perform a time ‐lapse analysis of tumor response in patients with STS treated with trabectedin from 2 phase II clinical trials.We examined 66 patients with translocation ‐related sarcoma registered in 2 Japanese phase II clinical trials. All patients previously received standard therapy before the administration of trabectedin at 1.2 mg/m2 every 3  weeks. Imaging evaluation was performed according to the study protocol. The sum of the maximum diameters of the target lesions was calculated and analyzed over time.Among the 66 patients, 9 (13.6%) showed partial response (PR) to trabectedin. H...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Salas Jiguet-Jiglaire Soft tissue sarcoma (STS) are rare and aggressive tumours. Their classification includes numerous histological subtypes of frequent poor prognosis. Liposarcomas (LPS) are the most frequent type among them, and the aggressiveness and deep localization of dedifferentiated LPS are linked to high levels of recurrence. Current treatments available today lead to five-year overall survival has remained stuck around 60%–70% for the past three decades. Here, we highlight a correlation between Aurora kinasa A (AURKA) and AURKB mRNA overexpression and a low metastasis - free survival. AURKA and ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study aims to assess the effect of cryoablation on non-target pulmonary lesions in immunotherapy patients with metastatic leiomyosarcoma or liposarcoma.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific e-Poster Source Type: research
Publication date: Available online 15 February 2020Source: Seminars in Ultrasound, CT and MRIAuthor(s): Gitanjali Bajaj, Harika Tirumani, Michella Whisman, Surbhi Raichandani, Roopa Ram, Kedar Jambhekar, Jerad M. Gardner, Tarun PandeyAbstractSoft-tissue sarcomas are a diverse group of rare mesenchymal malignancies accounting for only 1% of all solid adult malignancies. These have been categorized in 12 broad groups by the World Health Organization (WHO) with their recent update in 2013. Majority of them lack specific imaging features serving as imaging conundrums for a radiologist. These are often large masses at presentat...
Source: Seminars in Ultrasound, CT and MRI - Category: Radiology Source Type: research
Opinion statementOver the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel, that were shown to have efficacy in unselected populations of patients with soft tissue sarcomas. More recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and ...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionIn this retrospective evaluation, additional application of IORT does not significantly influence oncological outcome in retroperitoneal soft tissue sarcoma. Randomized trials are needed to clarify the benefit of IORT.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Conclusion: Our findings highlight the highly expression of SR-B1 in liposarcomas. SR-B1 may be a potential biomarker for the diagnosis of liposarcoma and may indicate the degree of differentiation of liposarcomas.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
mes L. Chen Soft tissue sarcomas (STS) are diverse tumors with heterogenous alterations. Platforms to detect circulating tumor DNA (ctDNA) have rapidly increased in popularity as they may avoid invasive biopsy morbidity. However, ctDNA profiling concordance with standard solid tumor comprehensive genomic profiling (CGP) is poorly characterized. Here, we report the outcomes of a single-institution experience comparing mutational results from commercial ctDNA and solid tumor CGP in advanced STS subjects. We identified STS subjects who had undergone solid tumor based CGP in four distinct cohorts: Dedifferentiated liposarc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionMedicine cannot provide much care for these advanced cases of multicentric liposarcoma so far. Therefore, more research should be conducted to improve the ability to manage these entities and to identify potential novel therapies.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
More News: Brachytherapy | Cancer & Oncology | Liposarcoma | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Sarcomas | Soft Tissue Sarcoma | Toxicology